<Disease><Name>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD)</Name><Synonym>THYMINE-URACILURIA, HEREDITARY;5-FLUOROURACIL TOXICITY</Synonym><OMIM><Number>274270</Number><URL>http://omim.org/entry/274270</URL></OMIM><Orphanet><Number>1675</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=1675</URL></Orphanet><Protein><Number>Dihydropyrimidine dehydrogenase [NADP(+)]</Number><URL>http://www.uniprot.org/uniprot/Q12882</URL></Protein><ExPASy><Number>1.3.1.2</Number><URL>http://enzyme.expasy.org/EC/1.3.1.2</URL></ExPASy><Gene>1p21.3Detail information to gene locus by the National Center for Biotechnology Information NCBI:

Dihydropyrimidine dehydrogenase
</Gene><ICD>E79.8</ICD><Summary>rare;autosomal recessive ;mutation in the DPYD gene ;unexpected severe 5FU toxicity;The spectrum of clinical presentations in subjects with the full biochemical phenotype of DPD ;deficiency ;ranges from asymptomatic individuals to severely affected patients suffering from seizures, microcephaly, muscular hypotonia, developmental delay and eye abnormalities [Fleger M et al. 2017]</Summary><Symptoms><symtomp><id>4028</id><symptom>attention deficit disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1956</id><symptom>behavior, autism or autistic-like / behaviour, autism or autistic-like</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1955</id><symptom>behavior, hyperactive, restless / behaviour, hyperactive, restless</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2226</id><symptom>cerebral atrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1774</id><symptom>cleft eyelid (coloboma)</symptom><category>EYES</category></symtomp><symtomp><id>3460</id><symptom>cognitive impairment / cognitive dysfunction</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3204</id><symptom>corpus callosum, agenesis/hypoplasia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3819</id><symptom>developmental delay</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2160</id><symptom>EEG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1724</id><symptom>eye movements, abnormal</symptom><category>EYES</category></symtomp><symtomp><id>2095</id><symptom>failure to thrive</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp><symtomp><id>1979</id><symptom>feeding difficulties, poor feeding</symptom><category>GASTROINTESTINAL SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1882</id><symptom>growth retardation, poor growth</symptom><category>GENERAL TOPICS | GENERAL TOPICS</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1896</id><symptom>hypertonia, spasticity</symptom><category>MUSCLES</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1886</id><symptom>microcephaly (&lt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2466</id><symptom>microphthalmus</symptom><category>EYES</category></symtomp><symtomp><id>1941</id><symptom>motor retardation / motor developmental delay</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2426</id><symptom>MRI, brain, white matter abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1717</id><symptom>no clinical symptoms (probably) / no clinical  significance</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1723</id><symptom>nystagmus</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1739</id><symptom>optic atrophy</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2089</id><symptom>Organic acids, urine</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1874</id><symptom>speech development, delayed, abnormal</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3902</id><symptom>white matter changes, abnormalities</symptom><category>NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>1700</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>2.60</min><max>22.80</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1821</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>8.00</min><max>110.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1842</id><name>Thymine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1990</id><name>5-Hydroxymethyluracil</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>1.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>93</id><name>Thymine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>19</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>22.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1333</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>10.00</min><max>50.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>451</id><name>Uric acid</name><specimen>urine</specimen><value>normal/inc</value><min>527.00</min><max>790.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1535</id><name>Uric acid</name><specimen>urine</specimen><value>normal/inc</value><min>222.00</min><max>287.00</max><unit>mmol/mol creatinine</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>776</id><name>Uric acid</name><specimen>urine</specimen><value>normal/inc</value><min>820.00</min><max>1026.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>417</id><name>Uric acid</name><specimen>serum</specimen><value>normal/inc</value><min>120.00</min><max>350.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>6772</id><title>Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1</title><author>van Kuilenburg ABP,</author><journal>JIMD Rep</journal><year>2019</year><book /><volume>45</volume><number>0</number><pages>65-69</pages><co_aut>et al.</co_aut></literature><literature><id>6771</id><title>Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency</title><author>Henricks LM,</author><journal>Int J Cancer</journal><year>2018</year><book /><volume>142</volume><number>2</number><pages>424-430</pages><co_aut>et al.</co_aut></literature><literature><id>6773</id><title>Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense var</title><author>van Kuilenburg ABP,</author><journal>Hum Mutat</journal><year>2018</year><book /><volume>39</volume><number>7</number><pages>947-953</pages><co_aut>et al.</co_aut></literature><literature><id>7940</id><title>Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity^^</title><author>Fidai SS,</author><journal>Autops Case Rep</journal><year>2018</year><book /><volume>8</volume><number>4</number><pages>e2018049</pages><co_aut>et al.</co_aut></literature><literature><id>6333</id><title>Dihydropyrimidine Dehydrogenase Deficiency: Metabolic Disease or Biochemical Phenotype?</title><author>Fleger M,</author><journal>JIMD Rep</journal><year>2017</year><book /><volume>37</volume><number>0</number><pages>49-54</pages><co_aut>et al.</co_aut></literature><literature><id>3919</id><title>Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activit</title><author>Meulendijks D,</author><journal>Cancer Treat Rev</journal><year>2016</year><book /><volume>50</volume><number>0</number><pages>23-34</pages><co_aut>et al.</co_aut></literature><literature><id>3918</id><title>Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice</title><author>Papanastasopoulos P,</author><journal>Anticancer Res</journal><year>2014</year><book /><volume>34</volume><number>4</number><pages>1531-1535</pages><co_aut>Stebbing J</co_aut></literature><literature><id>5973</id><title>Neurological disorders of purine and pyrimidine metabolism</title><author>Micheli V,</author><journal>Curr Top Med Chem</journal><year>2011</year><book /><volume>11</volume><number>8</number><pages>923-947</pages><co_aut>et al.</co_aut></literature><literature><id>6145</id><title>A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutatio</title><author>Weidensee S,</author><journal>Clin Biochem</journal><year>2011</year><book /><volume>44</volume><number>8</number><pages>722-724</pages><co_aut>et al.</co_aut></literature><literature><id>3920</id><title>Disorders of purine and pyrimidine metabolism</title><author>Nyhan WL</author><journal>Mol Genet Metab</journal><year>2005</year><book /><volume>86</volume><number>1</number><pages>25-33</pages><co_aut /></literature><literature><id>3921</id><title>Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency</title><author>van Kuilenburg AB,</author><journal>Ann Clin Biochem</journal><year>2003</year><book /><volume>40</volume><number>0</number><pages>41-45</pages><co_aut>vaDe Abreu RA, van Gennip AH</co_aut></literature><literature><id>6092</id><title>Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spe</title><author>Ito T,</author><journal>Clin Chem</journal><year>2000</year><book /><volume>46</volume><number>4</number><pages>445-452</pages><co_aut>et al.</co_aut></literature><literature><id>1023</id><title>Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency</title><author>van Kuilenburg AB</author><journal>Hum Genet</journal><year>1999</year><book /><volume>104</volume><number>0</number><pages>1-9</pages><co_aut>et al.</co_aut></literature><literature><id>117</id><title>Hereditary orotic aciduria and disorders of pyrimidine metabolism</title><author>Webster DR</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>0</number><pages>1799-1837</pages><co_aut>et al.</co_aut></literature><literature><id>226</id><title>Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation and ocular abnormalities</title><author>Bakker HD</author><journal>J Inherit Metab Dis</journal><year>1994</year><book /><volume>17</volume><number>5</number><pages>640-641</pages><co_aut>et al.</co_aut></literature><literature><id>856</id><title>A new case of dihydropyrimidine dehydrogenase deficiency</title><author>Brockstedt M</author><journal>J Inherit Metab Dis</journal><year>1990</year><book /><volume>13</volume><number>0</number><pages>124-124</pages><co_aut>et al.</co_aut></literature><literature><id>857</id><title>Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-i</title><author>Diasio RB</author><journal>J Clin Invest</journal><year>1988</year><book /><volume>81</volume><number>0</number><pages>47-51</pages><co_aut>Beavers TL, Carpenter JT</co_aut></literature><literature><id>855</id><title>Dihydropyrimide dehydrogenase deficiency leading to thymine-uraciluria: an inborn error of pyrimidine metabolism</title><author>Berger R</author><journal>Clin Chim Acta</journal><year>1984</year><book /><volume>141</volume><number>0</number><pages>227-234</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>